Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 Sacituzumab Govitecan vs Standard of Care in Previously Treated ES-SCLC
jRCT2071250006Phase 3Recruiting
- Sponsor
- Gilead Sciences
- Start
- Jun 2025
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 2
01
Overview
Phase 3, randomised, open-label trial of sacituzumab govitecan in small cell lung cancer (SCLC) (4 arms), sponsored by Gilead Sciences. Primary endpoint: Overall Survival. Started Jun 2025; status: recruiting.
02
Drugs
sacituzumab govitecan
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on jRCT2071250006.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2071250006.